INTRODUCTION AND OBJECTIVES: Successful benign prostatic hyperplasia (BPH) surgery has been previously linked to various patient and technical factors. Although proficiency of the surgeon is assumed to contribute to successful surgical outcomes, this link has not been explored in BPH surgery. We examined our institutional experience to determine if surgeon-specific variation exists for outcomes after BPH surgery.
METHODS: From January 2008 to December 2015, we identified 184 patients who received BPH surgery from seven attending surgeons. Measures to define successful BPH surgery included postoperative AUA symptom score of less than 8 (AUA symptom score success) and no BPH medications (medication success) at 4 months postoperatively. Multivariate logistic regression was performed (controlling for preoperative patient characteristics, medications taken, tests performed, surgical technique, operative time, and surgeon) in order to identify predictors of AUA symptom score and medication success. P-values less than 0.05 were considered significant.
RESULTS: All surgeons performed a similar number of cases during the observed time period (n¼22, 19, 22, 20, 24, 29, and 48; for surgeons 1, 2, 3, 4, 5, 6, and 7, respectively) . The unadjusted percentage of patients who achieved a successful outcome is summarized in Figure 1 , by surgeon. On multivariate logistic regression, controlling for all measured variables, surgeon was a significant predictor of AUA symptom score success (largest difference was for surgeon 6 versus surgeon 1; OR ¼ 11.2, 95% CI 2.3 to 53.9, p <0.01). The only other significant predictor for AUA symptom score success was preoperative post-void residual (OR¼3.1, p¼0.03). Additionally, surgeon was a significant predictor of medication success (largest difference was for surgeon 6 versus surgeon 1; OR ¼ 20.7, 95% CI 3.9 to 108, p <0.01). The only other significant predictor for medication success was patient comorbidity (OR¼0.38, p¼0.05).
CONCLUSIONS: Although successful BPH surgery is dependent on various patient and technical factors, the surgeon performing BPH surgery was the strongest predictor of outcomes at our institution. More specific metrics to rate surgeon quality are needed to better understand the underlying cause of significant surgeon-to-surgeon variation.
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MP27-17 3 YEAR RESULTS OF A PROSPECTIVE MULTI-CENTER STUDY ON LOCAL ANESTHESIA FOR THE PROSTATIC URETHRAL LIFT (PUL)
Steven Gange*, Salt Lake City, UT; Neal Shore, Myrtle Beach, SC; Sheldon Freedman, Las Vegas, NV; William Moseley, San Diego, CA; Sean Heron, St. Petersburg, United Arab Emirates; Ronald Tutrone, Baltimore, MD; Thomas Brown, Daytona Beach, FL; Jack Barkin, Toronto, Canada INTRODUCTION AND OBJECTIVES: The Prostatic Urethral Lift (PUL) is a minimally invasive procedure for lower urinary tract symptoms (LUTS) that may be conducted in the office setting. In order to characterize procedure tolerance under local anesthesia, peri-operative recovery, and long-term outcomes, PUL was studied in a multicenter, prospective, non-randomized trial.
METHODS: At 7 US centers, 51 men with International Prostate Symptom Score (IPSS)>12, peak flow rate ¼ 12mL/s, and prostate volume < 80cc were treated with PUL wherein UroLift' implants were transurethrally placed into the lateral lobes to enlarge the urethral lumen. Patient experience was measured via validated instruments including pelvic pain visual analog scale (VAS), Quality of Recovery VAS (QoR), Patient General Impression Index (PGI-I), Work Productivity and Activity Impairment Questionnaire (WPAI).
RESULTS: All procedures were well tolerated under local anesthesia. Symptom relief was significant by 1 month (IPSS 48%, QoL 44%) and sustained through 3 years (IPSS 42%, QoL 50%). 80% of patients were catheter free after PUL and the average for all patients was less than one day. There was no de novo, sustained occurrence of ejaculatory or erectile dysfunction. By one month, 86% of subjects achieved high quality recovery per QoR, 90% reported improvement through PGI-I, 96% had returned to pre-operative activity, 100% of employed subjects had returned to work. Average erectile function scores did not change, and both ejaculatory function and bother were improved (p<0.001).
CONCLUSIONS: The PUL procedure is well tolerated under local anesthesia, rarely requires postoperative catheterization, and is associated with high quality recovery experiences. In addition, the results of this study indicate that PUL provides durable symptom relief to patients, as IPSS and quality of life scores remain significantly improved at 3 years. PUL offers patients a minimally invasive option for rapid, sustained LUTS relief and preserved sexual function. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e335
